ARYA SCIENCES ACQUISITION CORP.
Completed 2020-07-01- CIK 1746037
- ARYA
- Now IMTX
- IPO 2018-10-09
- $149M trust
- 73 filings
Successfully merged with Immatics • Now trading as IMTX
- IPO Size
- $144M
- raised at the IPO
- Trust
- $149M
- as of 2020-03-31
- Current Status
- Completed
- from its latest filing
- IPO Year
- 2018
- year it listed
Filings, by quarter
73 filings over 15 quarters; violet bars carry a milestone
- 18 Q3: 7 filings
- 18 Q4: 19 filings
- 19 Q1: 7 filings
- 19 Q2: 1 filing
- 19 Q3: 1 filing
- 19 Q4: 1 filing
- 20 Q1: 12 filings
- 20 Q2: 8 filings
- 20 Q3: 10 filings
- 20 Q4: 0 filings
- 21 Q1: 6 filings
- 21 Q2: 0 filings
- 21 Q3: 0 filings
- 21 Q4: 0 filings
- 22 Q1: 1 filing
- S-1 filed 18 Q3
- IPO 18 Q4
- Definitive agreement 20 Q1
- Completed 20 Q3
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
ARYA Sciences Acquisition Corp. is a blank-check company formed to effect an initial business combination with one or more businesses. Its stated focus is healthcare and related industries, particularly North American or European companies in life sciences and medical technology.
Investment Focus
Healthcare, Technology
Geographic Focus
North America, Europe
Key Information
As the filings state it
- IPO Date
- 2018-10-09
- PIPE
- $104M
- Jurisdiction of Incorporation
- Cayman Islands
- SIC
- 6770
- Completion Date
- 2020-07-01
- Merger Target
- Immatics
- SPAC Ticker
- ARYA
- Merged Ticker
- IMTX
Stock Performance
IMTXTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2018-12-12 | $0.00 | |
| At Merger | 2020-07-02 | $15.05 | +Infinity% |
| 6 Months Post-Merger | 2021-01-04 | $11.00 | -27% |
| 1 Year Post-Merger | 2021-07-02 | $11.81 | -22% |
| 2 Years Post-Merger | 2022-07-05 | $8.96 | -40% |
| Current Price | 2026-10-16 | $6.73 | +Infinity% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The sponsor is an affiliate of Perceptive Advisors, a healthcare-focused investment firm. Its team includes experienced healthcare investors, scientists, physicians and financial analysts, alongside executives with life sciences, biotechnology, diagnostics and medical-device leadership experience.